Skip to content

Investigation of the Anti-hypertensive Role of Specific Plant Extracts in Hypertenison Patients

Investigation of the Anti-hypertensive Role of Specific Plant Extracts in Hypertenison Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015987
Enrollment
Unknown
Registered
2018-05-04
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

placebo group:oral placebo
experimental group 1:oral chokeberry extract
experimental group 2:oral tamato extract(fruitflow)
experimental group 3:oral cocoa extract
experimental group 4:oral casein-derived peptide formulas

Sponsors

Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old; 2. Grade I Hypertension SBP 140-159 or DBP 90-99 mmHg; 3. Have normal understanding and expression skills; 4. Informed consent.

Exclusion criteria

Exclusion criteria: 1. persons aged under 18 or above 65, pregnant or lactating women, allergic to the supplements; 2. Diabetes; 3. Obesity: BMI=28 kg/m2; 4. Target organ damage; 5. Diagnosis of cerebrovascular disease, heart disease, kidney disease, peripheral vascular disease, retinopathy; 6. Secondary hypertension patients; 7. Taking drugs that make blood pressure increased in recent 3 months: such as oral contraceptives, endosulfan, nasal drops, cocaine, amphetamine, steroids, non-steroidal anti-inflammatory drugs, erythropoietin, cyclosporine and licorice; 8. Patients are being treated with antibiotics, antibacterial, antiviral, chemotherapy, sterols, or immunotherapy; 9. Subjects who participate in research intervention in recent 30 days; Any other condition that may cause the subject to be at risk or may cause the subject to fail to understand or comply with the test requirements (the researchers determined). Withdraw criteria: 1. Subjects with poor compliance, taking less than the prescribed amount of 80% of the supplements or more than the required amount of 120%; 2. Suspension of research or failure to complete all examination items; 3. do not follow the research plan.

Design outcomes

Primary

MeasureTime frame
blood pressure index;

Secondary

MeasureTime frame
lipids profile;glucose;inflammatory markers;Oxidative stress parameters;Endothelial function markers;

Countries

China

Contacts

Public ContactLi-Hua Chen

Soochow University

chenlihua@suda.edu.cn+86 51265880075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026